Pfizer’s chief financial officer Dave Denton will soon wave goodbye to the world of pharma, pivoting back to the consumer goods industry four years after he joined the ranks of the New York drugmaker in the wake of its COVID-19 windfall.
Denton is due to pass the baton on August 15, Pfizer announced Thursday. The CFO will take up a “professional opportunity outside of the pharmaceutical industry in consumer goods,” leaving SVP of finance at Pfizer’s global biopharmaceutical business, Cecile Guegan, to take up the finance chief position in an interim basis. Pfizer noted that it's also kicking off an internal and external search for a permanent successor to the post.
CEO Albert Bourla called Denton a “a steady and trusted steward of Pfizer’s financial health,” pointing to his leadership during “some of the most important business transactions in our recent history,” including the acquisitions of Seagen, Biohaven and Metsera, which will “serve Pfizer well for years to come.”
“We wish him the very best as he returns to the consumer goods industry,” Bourla said in a company release.
Related
